NorthLinks Bio Launches with $34 Million Financing to Advance Broad-Spectrum Respiratory Antiviral Platform

Funding Rounds

▤ Summary

NorthLinks Bio launched as a US-based clinical-stage biotechnology company after reorganizing from Pneumagen Ltd. It also closed a $34 million financing led by RA Capital Management. The funding will support HEX17, the company’s intranasal antiviral candidate, as it moves toward Phase 2b readiness. NorthLinks Bio will also use the capital to expand US operations, support manufacturing, and continue research in Scotland.

$ Funding

$
Amount $34.0M Total raised
□
Date June 23, 2026 Announcement date
◎
Investors RA Capital Management Lead investors
▥
Company northlinksbio.com Funded company

◇ AskAI Classifications

Sectors
No sectors detected
Functions
No functions detected

▦ Linked Companies